메뉴 건너뛰기




Volumn 16, Issue 1, 2017, Pages

Increased amputation risk with canagliflozin treatment: Behind the large cardiovascular benefit?

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85030831513     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0611-x     Document Type: Note
Times cited : (35)

References (19)
  • 2
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
    • Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-72.
    • (2016) Circulation , vol.134 , Issue.10 , pp. 752-772
    • Heerspink, H.J.1    Perkins, B.A.2    Fitchett, D.H.3    Husain, M.4    Cherney, D.Z.5
  • 4
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-82.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.4 , pp. 372-382
    • Stenlof, K.1    Cefalu, W.T.2    Kim, K.A.3    Alba, M.4    Usiskin, K.5    Tong, C.6    Canovatchel, W.7    Meininger, G.8
  • 5
    • 84898791440 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
    • Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-77.
    • (2014) Diabetes Obes Metab , vol.16 , Issue.5 , pp. 467-477
    • Forst, T.1    Guthrie, R.2    Goldenberg, R.3    Yee, J.4    Vijapurkar, U.5    Meininger, G.6    Stein, P.7
  • 6
    • 84930844091 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
    • Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-11.
    • (2015) Diabetes Care , vol.38 , Issue.3 , pp. 403-411
    • Neal, B.1    Perkovic, V.2    Zeeuw, D.3    Mahaffey, K.W.4    Fulcher, G.5    Ways, K.6    Desai, M.7    Shaw, W.8    Capuano, G.9    Alba, M.10
  • 7
    • 85017368135 scopus 로고    scopus 로고
    • Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
    • Karagiannis T, Bekiari E, Tsapas A. Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evid. 2017;12:1-10.
    • (2017) Core Evid , vol.12 , pp. 1-10
    • Karagiannis, T.1    Bekiari, E.2    Tsapas, A.3
  • 8
    • 84975318811 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
    • Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 89
    • Inagaki, N.1    Harashima, S.2    Maruyama, N.3    Kawaguchi, Y.4    Goda, M.5    Iijima, H.6
  • 10
    • 85024835007 scopus 로고    scopus 로고
    • SGTL2 inhibitors and amputations in the US FDA adverse event reporting system
    • Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol. 2017;5(9):680-1.
    • (2017) Lancet Diabetes Endocrinol , vol.5 , Issue.9 , pp. 680-681
    • Fadini, G.P.1    Avogaro, A.2
  • 11
    • 84859021291 scopus 로고    scopus 로고
    • Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988-2008
    • Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: US, 1988-2008. Diabetes Care. 2012;35(2):273-7.
    • (2012) Diabetes Care , vol.35 , Issue.2 , pp. 273-277
    • Li, Y.1    Burrows, N.R.2    Gregg, E.W.3    Albright, A.4    Geiss, L.S.5
  • 12
    • 84950119656 scopus 로고    scopus 로고
    • Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the fremantle diabetes study
    • Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the fremantle diabetes study. Cardiovasc Diabetol. 2015;14:152.
    • (2015) Cardiovasc Diabetol , vol.14 , pp. 152
    • Baba, M.1    Davis, W.A.2    Norman, P.E.3    Davis, T.M.4
  • 14
    • 84886719687 scopus 로고    scopus 로고
    • Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study
    • Winell K, Venermo M, Ikonen T, Sund R. Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study. Eur J Vasc Endovasc Surg. 2013;46(5):569-74.
    • (2013) Eur J Vasc Endovasc Surg , vol.46 , Issue.5 , pp. 569-574
    • Winell, K.1    Venermo, M.2    Ikonen, T.3    Sund, R.4
  • 15
    • 61849115759 scopus 로고    scopus 로고
    • Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations
    • Johannesson A, Larsson GU, Ramstrand N, Turkiewicz A, Wirehn AB, Atroshi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care. 2009;32(2):275-80.
    • (2009) Diabetes Care , vol.32 , Issue.2 , pp. 275-280
    • Johannesson, A.1    Larsson, G.U.2    Ramstrand, N.3    Turkiewicz, A.4    Wirehn, A.B.5    Atroshi, I.6
  • 18
    • 85021054097 scopus 로고    scopus 로고
    • Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials
    • Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34(7):1707-26.
    • (2017) Adv Ther , vol.34 , Issue.7 , pp. 1707-1726
    • Kohler, S.1    Zeller, C.2    Iliev, H.3    Kaspers, S.4
  • 19
    • 85030843541 scopus 로고    scopus 로고
    • Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study
    • Yuan Z, DeFalco FJ, Ryan PB, Schuemie MJ, Stang PE, Berlin JA, Desai M, Rosenthal N. Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab. 2017. doi: 10.1111/dom.13115.
    • (2017) Diabetes Obes Metab
    • Yuan, Z.1    DeFalco, F.J.2    Ryan, P.B.3    Schuemie, M.J.4    Stang, P.E.5    Berlin, J.A.6    Desai, M.7    Rosenthal, N.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.